featur
chemistri
pyrazolepyrazolin
pharmacolog
attract
scaffold
describ
number
review
main
approach
synthesi
mention
heterocycl
biolog
activ
analyz
howev
pyrazolepyrazolin
ethiazolidinebas
hybrid
biolog
activ
compound
poorli
discuss
context
pharmacophor
hybrid
approach
therefor
purpos
review
summar
data
synthesi
modif
heterocycl
system
thiazolidin
pyrazolin
pyrazol
fragment
molecul
promis
object
modern
bioorgan
medicin
chemistri
descript
biolog
activ
focus
sar
analysi
mechanist
insight
mention
hybrid
pharmacophor
hybrid
approach
current
concept
drug
design
develop
produc
molecul
improv
affin
efficaci
review
deal
concept
molecular
hybrid
promiseschalleng
associ
hybrid
molecul
along
recent
advanc
anticanc
hybrid
variou
heteroaryl
base
hybrid
particular
isatin
coumarin
indolinethiazolidinon
recent
review
conjug
remark
inhibitori
potenti
design
new
druglik
small
molecul
base
pharmacolog
attract
scaffold
thiazolidin
pyrazol
pyrazolin
reason
promis
direct
modern
medicin
chemistri
chemic
approach
synthesi
thiazolidinoneand
pyrazolebas
deriv
pharmacolog
activ
describ
numer
review
howev
pyrazolepyrazolineethiazolidinebas
conjug
biolog
activ
compound
poorli
review
context
pharmacophor
hybrid
approach
recent
synthet
studi
pyrazoleethiazolidin
relat
hybrid
biolog
investig
antitumor
antimicrobi
antivir
antiparasit
antiinflammatori
activ
allow
identifi
promis
druglik
compound
thu
pyrazoleethiazolidinonesthiazol
patent
inhibitor
necroptosi
vhr
protein
tyrosin
phosphatas
inhibitor
compound
compound
modul
rnabind
protein
activ
proapoptot
bax
addit
pyrazoleethiazolidinon
hybrid
studi
possibl
inhibit
interact
inhibitor
histon
acetyltransferas
inhibitor
cox
enzym
therefor
purpos
review
summar
data
synthesi
biolog
activ
heterocycl
system
thiazolidin
pyrazolepyrazolin
fragment
molecul
promis
pyrazoleethiazolidinonethiazol
hybrid
target
heterocycl
review
fragment
hybrid
molecul
depict
fig
review
hybrid
classifi
pyrazolinesubstitut
thiazolidin
base
linkag
target
heterocycl
core
basic
approach
synthesi
mention
deriv
provid
combin
two
small
molecul
aminolysi
reaction
acyl
knoevenagel
procedur
heterocycl
monocycl
compound
via
cycliz
reaction
yield
seri
noncondens
bicycl
system
detail
biolog
activ
evalu
pyrazolineethiazolidinon
conjug
pyrazolineethiazol
fig
synthes
via
cyclocondens
nbinucleophil
reaction
equival
dielectrophil
synthon
allow
identifi
compound
antimicrobi
antivir
antiinflammatori
antitumor
insecticid
activ
synthesi
target
deriv
ahalogenocarboxyl
acid
ethyl
ester
maleic
anhydrid
maleimid
baroylacryl
acid
dimethyl
acetylenedicarboxyl
bromoacetophenon
ethyl
use
equival
dielectrophil
synthon
threecompon
onepot
reaction
includ
cyclocondens
chloroacet
acid
knoevenagel
reaction
aromat
aldehyd
isatin
deriv
effect
approach
design
new
anticanc
agent
among
pyrazolineethiazolidinon
fig
reaction
pyrazolylimin
pyrazolylhydrazon
thioglycol
acid
ester
wide
use
approach
synthesi
conjug
vhr
protein
tyrosin
phosphatas
inhibitor
n
n
hatinhibitor
rna
bind
protein
modul
proapoptot
bax
activ
tnfa
inhibitor
pyrazol
moieti
posit
khodairi
propos
synthesi
benzopyrano
fragment
use
ncyanoacetylbenzopyranopyrazolon
start
compound
fig
anoth
direct
synthesi
pyrazolesubstitut
thiazolin
fig
realiz
creation
pyrazol
moieti
via
reaction
trifluoromethyl
acetoaceton
broad
group
pyrazoleethiazolidinon
deriv
exemplifi
pseudothiohydantoin
synthes
via
cyclocondens
pyrazol
substitut
asymmetr
bisthiourea
nbinucleophil
equival
dielectrophil
synthon
ethyl
dimethyl
acetylenedicarboxyl
simultan
bioisoster
obtain
reaction
thiourea
abromoacetophenon
fig
aim
search
new
anticanc
antimicrobi
compound
among
pyrazoleethiazolidinon
conjug
pyrazolesulfonylthiourea
use
start
materi
reaction
compound
ethyl
abromoacetophenon
result
format
correspond
pyrazoleethiazolidinon
pyrazolethiazolidin
sulfonylimin
linker
group
fig
anoth
approach
synthesi
pyrazol
deriv
pseudothiohydantoin
suggest
b
insuasti
et
al
synthesi
target
compound
carri
via
aminolysi
fig
row
synthes
via
cyclocondens
thiosemicarbazon
ahalogenocarboxyl
acid
deriv
maleic
anhydrid
pyrazol
bioisoster
thiazolidin
fragment
obtain
reaction
thiosemicarbazon
chloroacet
acid
pyridin
abromoacetophenon
howev
reaction
thiosemicarbazon
acet
anhydrid
iron
chlorid
accompani
format
pyrazoleethiadiazol
deriv
fig
pyrazolesubstitut
thiosemicarbazid
use
synthesi
pyrazoleethiazolidinon
carbohydrazid
linker
group
threecompon
onepot
reaction
thiosemicarbazid
chloroacet
acid
aromat
aldehyd
accompani
format
correspond
modif
sulfur
acid
medium
gave
pyrazoleethiadiazol
reaction
compound
abromoacetophenon
accompani
format
correspond
pyrazolethiazolidin
conjug
fig
synthesi
achiev
via
cyclocondens
pyrazolebas
asymmetr
thiourea
nbinucleophil
see
fig
time
numer
paper
repres
data
obtain
diazol
moieti
posit
compound
fig
particular
via
reaction
thiourea
ethylchloroacet
dithiocarbam
method
rhodanin
synthesi
conveni
often
use
variant
synthesi
deriv
base
cyclocondens
rm
mohareb
et
al
success
appli
dithiocarbam
method
synthesi
via
twostag
process
base
reaction
carbon
disulfid
alkalin
medium
subsequ
cycliz
variou
synthes
reaction
amercaptocarboxyl
acid
especi
thioglycol
acid
isothiocyan
ren
c
thu
pyrazoleethiazolidinon
phenyl
sulfonamid
linker
group
obtain
base
mention
approach
describ
synthesi
polyheterocycl
deriv
base
reaction
thioglycol
acid
correspond
imin
methylidenehydrazyd
threecompon
reaction
involv
thioglycol
acid
aromat
aldehyd
heterocycl
amin
contain
diazol
fragment
reaction
isatin
heterocycl
amin
led
schiff
base
react
thioglycol
acid
form
indolinespirothiazolidinon
fig
reaction
trithiocarbonyl
diglycol
acid
amin
alcohol
alcoholewat
medium
holmberg
synthesi
conveni
effect
method
synthesi
rhodanin
especi
base
aromat
amin
carboxyl
acid
hydrazid
mention
reaction
use
augustin
et
al
synthesi
rhodanin
benzopyrazol
fragment
posit
fig
method
synthesi
pyrazoleethiazolidinon
fig
acetamid
linker
group
propos
base
reaction
acid
dmf
presenc
hatu
bi
dimethylamino
methylen
pyridinium
hexafluorophosph
synthesi
structur
relat
azolidineepyrazolin
propos
base
nalkyl
reaction
potassium
salt
hydantoin
deriv
obtain
situ
fig
ethanon
success
use
alkyl
agent
success
modifi
diazo
coupl
reaction
use
pyrazolyl
diazonium
chlorid
yield
compound
fig
synthesi
pyrazolineeindolineethiazolidinon
conjug
realiz
knoevenagel
reaction
pyrazolineeisatin
acet
acid
medium
presenc
sodium
acet
fig
synthesi
pyrazoloneethiazolidinon
fig
achiev
base
reaction
isonitrosorhodanin
use
piperidin
basic
catalyst
magdi
allow
obtain
correspond
pyrazolethiazolidinon
use
hydrazin
hydrat
structur
final
compound
depend
reaction
medium
thu
pyrazol
obtain
alcohol
medium
presenc
sodium
ethyl
form
acet
acid
reaction
compound
presenc
sodium
ethyl
led
format
polyheterocycl
system
fig
synthesi
ethylen
linker
group
perform
via
cyclocondens
reaction
thiourea
gpyrazolylachlorobutano
see
pharmacolog
attract
rhodanin
fig
synthes
follow
heterocycl
phenylhydrazin
conjug
group
pyrazolineethiazolidinon
obtain
reaction
alcohol
medium
fig
synthes
compound
modifi
posit
thiazolidin
cycl
mannich
reaction
secondari
cyclic
amin
alkyl
reaction
form
follow
approach
synthesi
pyrazolineethiazolidinon
conjug
carbonyl
methyliden
linker
group
base
acyl
reaction
fig
reaction
substanc
chloroacetamid
via
nalkyl
reaction
led
deriv
explor
structureantitrypanosom
activ
relationship
pyrazolineethiazolidinon
conjug
synthes
reaction
fig
substitut
obtain
condit
continu
mention
studi
deriv
oxoethylaminomethylen
linker
group
synthes
modif
acid
reaction
pyrazolin
presenc
dcc
dicyclohexylcarbodiimid
fig
antitumor
activ
evalu
promis
thiazolidinon
pyrazolin
fragment
vitro
anticanc
activ
thiazolidinon
pyrazolin
cycl
posit
thiazolidin
test
nation
cancer
institut
nci
display
anticanc
activ
leukemia
melanoma
lung
colon
cn
ovarian
renal
prostat
breast
cancer
cell
line
effici
anticanc
compound
found
activ
select
influenc
colon
cancer
cell
line
especi
ht
lggi
sar
studi
reveal
anticanc
activ
compound
sensit
natur
substitu
posit
thiazolon
cycl
introduct
poh
group
fragment
enhanc
potenc
posit
isom
name
substitut
thiazolon
promis
compound
optim
fig
novel
pyrazolineethiazolidinoneeisatin
conjug
design
potenti
anticanc
agent
fig
effect
anticanc
compound
found
activ
mean
gi
attach
halogen
br
cl
isatin
scaffold
allow
gain
one
log
unit
activ
gi
level
comparison
isatin
analog
introduct
methyl
group
ch
cooh
group
isatin
fragment
led
loss
activ
natur
substitu
fragment
also
influenc
antitumor
activ
therefor
introduct
electronwithdraw
group
e
improv
antiprolif
activ
comparison
electrondonor
group
would
indic
decreas
electron
densiti
moieti
import
inhibitori
activ
substitut
phenyl
fragment
posit
pyrazolin
cycl
substitu
signific
influenc
antitumor
activ
introduct
group
mention
posit
limit
effect
method
result
studi
two
hitcompound
select
sar
analysi
show
determin
factor
express
antitumor
activ
structur
substitu
posit
thiazol
fig
modif
ester
group
hydrazid
subsequ
hydrazon
gave
potenti
antitumor
properti
time
pyrazolineethiazolidinon
signific
cytotox
seri
pyrazolineethiazolidinebas
compound
test
antitumor
activ
accord
standard
nci
protocol
deriv
pyrazolin
fragment
show
moder
cytostat
effect
group
public
includ
synthesi
pyrazolineethiazolidinon
pyrazolineethiazolidin
divers
substitut
pyrazol
core
analysi
mention
result
demonstr
modif
pyrazolin
fragment
crucial
implement
antineoplast
action
fig
statement
evidenc
level
effici
compound
moder
rate
effect
magdi
elzahar
et
al
synthes
group
benzofuranepyrazol
variou
heterocycl
includ
thiazol
thiazolidin
fragment
screen
antitumor
activ
line
liver
carcinoma
cell
line
hela
cervix
carcinoma
cell
line
interestingli
compound
show
select
effect
one
line
similar
fig
synthesi
studi
antitumor
activ
pyrazolethiazolidinoneetriazol
lung
cancer
line
conduct
arun
isloor
et
al
among
studi
conjug
compound
activ
effect
concentr
ic
mgml
presenc
otolyl
fragment
favor
anticanc
effect
substitut
naphthyl
ring
caus
complet
loss
activ
fig
import
achiev
studi
anticanc
pyrazolethiazolidinon
hybrid
compound
establish
necroptosi
inhibit
pseudothiohydantoin
deriv
pyrazol
moieti
posit
fig
among
deriv
potenti
inhibitor
identifi
phenol
phenyl
sulphanil
fragment
allow
get
fold
potenti
comparison
gener
note
presenc
substitu
posit
natur
crucial
implement
necroptosi
inhibitori
activ
chang
fluorin
atom
posit
accompani
loss
activ
author
synthes
group
relat
compound
aromat
heterocycl
triazol
isooxazol
establish
impact
pyrazol
cycl
activ
modif
result
loss
inhibitori
activ
confirm
import
pyrazol
moieti
analog
studi
antitumor
activ
pyrazolerhodanin
allow
identifi
compound
prove
effect
inhibitori
effect
tumor
line
micromolar
concentr
accord
nci
protocol
fig
substanc
character
select
effect
leukemia
lung
cancer
cell
line
e
especi
lung
cancer
valu
effect
concentr
cytotox
gi
mm
lc
mm
respect
manal
sarki
et
al
carri
synthesi
new
bisthiazolon
deriv
potenti
inhibitor
phosphatas
specifi
enzym
involv
cell
cycl
progress
unregul
tumor
develop
aim
investig
select
affin
compound
studi
protein
tyrosin
phosphatas
vhr
vaccinia
viru
relat
e
dualspecif
phosphatas
overal
compound
bisthiazolidinon
group
synthes
display
inhibitori
activ
micromolar
ic
valu
lower
correspond
monom
mention
group
compound
includ
thiazolidinoneeindazol
conjug
fig
establish
replac
fragment
indazol
accompani
select
inhibit
phosphatas
loss
inhibitori
activ
abolish
inhibit
screen
vitro
antitumor
activ
show
introduct
linker
group
heterocycl
promot
potenti
antitumor
activ
howev
modif
thiazolidinon
cycl
via
mannich
reaction
alkyl
effect
approach
optim
hitcompound
fig
search
new
antimicrobi
antifung
agent
among
pyrazolineethiazolidinon
relat
conjug
promis
direct
biolog
test
mention
compound
mervat
elenani
et
al
synthes
group
thiazol
pyrazolin
fragment
posit
studi
antimicrobi
activ
gramposit
staphylococcu
aureu
bacillu
subtili
gramneg
bacteria
escherichia
coli
pseudomona
aeruginosa
fungi
candida
albican
howev
compound
inact
microorgan
activ
b
subtili
appear
commensur
amoxacillin
propenicillin
fig
research
bakr
f
microorgan
mic
valu
rang
mgml
howev
among
group
compound
could
select
show
time
higher
bactericid
activ
experi
ampicillin
twice
activ
griseofulvin
fungi
mention
compound
show
highest
activ
valu
mic
mgml
p
aeruginosa
fig
cs
reddi
et
al
perform
synthesi
studi
antimicrobi
activ
thiazolidinoneepyrazol
b
subtili
aureu
e
coli
pyogen
establish
moder
effect
mention
compound
mic
mgml
fig
introduct
chlorin
nitro
hydroxyl
group
paraposit
benzen
ring
result
fold
potenti
activ
comparison
howev
replac
phenyl
moieti
pyridin
pyrimidin
particularli
effect
allow
get
fold
enhanc
effici
pyrazoleethiazolidinon
pyrazoleethiazol
coupl
hydrazon
linker
group
investig
promis
agent
antimicrobi
antifung
activ
found
compound
r
show
compar
activ
mic
mgml
ampicillin
e
coli
compound
r
cl
appear
activ
c
albican
mic
mgml
fig
overal
pyrazolethiazolidinon
higher
activ
relat
pyrazolethiazol
effect
bactericid
agent
strain
aureu
mic
mgml
show
signific
antifung
effect
cervesia
mic
mgml
evalu
antimicrobi
activ
thiazolidin
fragment
fig
reveal
effect
b
subtili
nctc
aureu
atcc
e
coli
atcc
p
aeruginosa
atcc
fungi
c
albican
tmru
niger
atcc
antimicrobi
screen
carri
gramposit
bacteria
aureu
b
subtili
mtcc
staphylococcu
epidermi
gramneg
bacteria
e
coli
mtcc
p
aeruginosa
mtcc
typhi
mtcc
k
pneumonia
mtcc
antifung
effect
studi
niger
mtcc
aspergillu
fumigatu
mtcc
aspergillu
flavu
mtcc
c
albican
mtcc
gener
test
compound
fig
show
promis
antimicrobi
activ
howev
could
emphas
bisspiroindolon
show
better
growth
inhibit
compar
compound
ss
reddi
et
al
propos
synthesi
pyrazolepyrimidineethiazolidinon
fig
studi
compound
furan
posit
thiazolidinon
show
higher
compar
efficaci
mic
mgml
fluconazol
among
compound
fig
investig
antimicrobi
activ
effect
pyrazolethiazolidinon
includ
thiophen
fragment
molecul
show
time
higher
effici
mic
mgml
comparison
deriv
moder
antimicrobi
activ
toward
e
coli
aureu
identifi
substitut
deriv
fig
pbromophenyl
substitut
deriv
show
highest
effici
e
coli
mic
mgml
time
less
activ
tetracyclin
mic
mgml
howev
promis
group
antimicrobi
agent
antimicrobi
activ
substanc
studi
methicillin
mrsa
quinoloneresist
qrsa
aureu
compound
exhibit
stronger
activ
standard
drug
norfloxacin
oxacillin
mic
valu
mgml
sar
analysi
pyrazolerhodanin
deriv
reveal
import
aryl
moieti
presenc
pyrazol
ring
express
antimicrobi
action
number
substitu
consider
increas
effect
identifi
fig
search
new
chemotherapeut
agent
among
pyrazoleethiazolidinon
limit
anticanc
antimicrobi
studi
evalu
antivir
antiparasit
activ
mention
hybrid
compound
allow
identifi
promis
hitcompound
conduct
sar
analysi
osama
elsabbagh
propos
synthesi
group
pyrazolineethiazolidinon
structur
relat
pyrazolineethiazol
fig
perform
studi
wide
rang
antivir
activ
note
describ
compound
show
select
activ
howev
one
deriv
ar
h
among
compound
moder
efficaci
herp
simplex
viru
type
herp
simplex
viru
type
vaccinia
viru
vesicular
stomat
viru
thymidin
kinasedefici
herp
simplex
viru
type
valu
effect
concentr
mgml
cytotox
valu
mg
ml
si
studi
thiazolidinon
sulfonamid
fragment
hepat
c
viru
conduct
yili
ding
et
al
allow
identifi
number
promis
antivir
agent
among
studi
pyrazol
deriv
fig
show
moder
effect
ic
mgml
ec
mgml
cytotox
index
cc
mgml
si
gener
test
compound
antivir
activ
sar
cov
screen
conduct
compound
fig
trypanosoma
brucei
brucei
tbb
trypanosoma
brucei
gambiens
tbg
result
show
moder
antitrypanosom
activ
compound
strain
test
parasit
activ
index
ic
tbb
mm
ic
tbg
mm
aim
investig
trypanocid
activ
pyrazolineethiazolidinon
conjug
synthesi
new
carri
fig
target
heterocycl
branch
methyliden
oxoethylaminomethyliden
linker
group
result
screen
trypanosoma
brucei
gambiens
allow
identifi
compound
suffici
antitrypanosom
activ
ic
mm
moder
low
cytotox
cc
studi
antiparasit
activ
pyrazolineethiazolidinon
fig
carri
towar
trypanosoma
cruzi
trypanosoma
b
rhodesiens
leishmania
donovani
plasmodium
falciparum
result
indic
moder
inhibitori
effect
trypanosoma
b
rhodesiens
ic
mgml
l
donovani
ic
mgml
higher
influenc
p
falciparum
ic
mgml
cytotox
index
cc
mgml
promis
direct
pharmacolog
investig
result
show
pyrazolineethiazolesthiazolidinon
possess
better
antiinflammatori
activ
percentag
reduct
paw
endema
control
group
ketoprofen
effici
e
compar
hexahydroindazol
analogu
compar
effect
thiazol
deriv
thiazolidinon
could
conclud
higher
activ
pyrazolineethiazol
hybrid
fig
detail
studi
pyrazolineethiazolidinon
potenti
inhibitor
allow
identifi
highli
activ
compound
ic
mm
best
select
index
si
effect
similar
celecoxib
sar
analysi
fig
result
show
depend
inhibit
natur
aryl
substitu
are
bring
pyrazolin
posit
structur
thu
compound
electrondonor
substitu
methyl
group
paraand
metaposit
are
better
inhibitori
effect
compar
chlorin
natur
substitu
paraposit
bcycl
also
signific
impact
inhibitori
activ
order
continu
develop
structur
analogu
celecoxib
adnan
bekhit
et
al
synthes
seri
pyrazoleethiazolidin
fig
antiinflammatori
activ
screen
use
cotton
pelletinduc
granuloma
carrageenaninduc
rat
paw
edema
bioassay
highli
activ
compound
test
abil
inhibit
well
ulcerogen
effect
acut
toxic
first
phase
studi
cotton
pellet
induc
granuloma
bioassay
allow
structur
modif
substitu
pyrazol
moieti
allow
establish
main
structur
criteria
increas
inhibitori
effect
amal
youssef
et
al
carri
synthesi
methylen
potenti
antiinflammatori
neuroprotect
agent
studi
conduct
vitro
vivo
allow
identifi
group
highli
activ
antiinflammatori
compound
low
ulcerogen
impact
satisfactori
toxicometri
paramet
base
vitro
experi
four
compound
select
vivo
studi
accord
screen
protocol
formalininduc
paw
edema
turpentin
oilinduc
granuloma
pouch
bioassay
establish
test
compound
show
activ
compar
celecoxib
concentr
mgkg
introduct
benzyl
moieti
posit
thiazolidinon
accompani
loss
antiinflammatori
activ
fig
review
articl
present
ration
approach
design
chemotherapeut
agent
base
molecular
hybrid
pharmacolog
attract
thiazolidin
pyrazol
pyrazolin
heterocycl
base
linkag
target
heterocycl
core
review
hybrid
classifi
pyrazolinesubstitut
thiazolidin
basic
approach
synthesi
pyrazolethiazolidinon
provid
combin
two
small
molecul
via
aminolysi
acyl
reaction
knoevenagel
procedur
heterocycl
monocycl
compound
via
cycliz
reaction
yield
seri
noncondens
bicycl
system
review
biolog
applic
focus
sar
analysi
mechanist
insight
thiazolidineepyrazol
hybrid
molecular
hybrid
tool
medicin
chemistri
success
use
design
biolog
activ
conjug
antitumor
activ
includ
inhibit
necroptosi
phosphatas
interact
activ
proapoptot
bax
antimicrobi
antifung
antivir
antiparasit
applic
well
antiinflammatori
properti
inhibitor
cox
enzym
abbrevi
adamt
disintegrin
metalloproteinas
thrombospondin
motif
bax
x
protein
cc
half
maxim
cytotox
concentr
dualspecif
phosphatas
cdc
name
refer
cell
divis
cycl
dcc
dicyclohexylcarbodiimid
dtp
develop
therapeut
program
ec
half
maxim
effect
concentr
ed
half
maxim
effect
dose
ic
half
maxim
inhibitori
concentr
